Cargando…

Endothelial Dysfunction and Diabetic Cardiomyopathy

The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Moran, Li, Yongsheng, Li, Sheng, Lv, Jiagao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021409/
https://www.ncbi.nlm.nih.gov/pubmed/35464057
http://dx.doi.org/10.3389/fendo.2022.851941
_version_ 1784689812030095360
author Wang, Moran
Li, Yongsheng
Li, Sheng
Lv, Jiagao
author_facet Wang, Moran
Li, Yongsheng
Li, Sheng
Lv, Jiagao
author_sort Wang, Moran
collection PubMed
description The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca(2+) mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.
format Online
Article
Text
id pubmed-9021409
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90214092022-04-22 Endothelial Dysfunction and Diabetic Cardiomyopathy Wang, Moran Li, Yongsheng Li, Sheng Lv, Jiagao Front Endocrinol (Lausanne) Endocrinology The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca(2+) mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9021409/ /pubmed/35464057 http://dx.doi.org/10.3389/fendo.2022.851941 Text en Copyright © 2022 Wang, Li, Li and Lv https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Moran
Li, Yongsheng
Li, Sheng
Lv, Jiagao
Endothelial Dysfunction and Diabetic Cardiomyopathy
title Endothelial Dysfunction and Diabetic Cardiomyopathy
title_full Endothelial Dysfunction and Diabetic Cardiomyopathy
title_fullStr Endothelial Dysfunction and Diabetic Cardiomyopathy
title_full_unstemmed Endothelial Dysfunction and Diabetic Cardiomyopathy
title_short Endothelial Dysfunction and Diabetic Cardiomyopathy
title_sort endothelial dysfunction and diabetic cardiomyopathy
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021409/
https://www.ncbi.nlm.nih.gov/pubmed/35464057
http://dx.doi.org/10.3389/fendo.2022.851941
work_keys_str_mv AT wangmoran endothelialdysfunctionanddiabeticcardiomyopathy
AT liyongsheng endothelialdysfunctionanddiabeticcardiomyopathy
AT lisheng endothelialdysfunctionanddiabeticcardiomyopathy
AT lvjiagao endothelialdysfunctionanddiabeticcardiomyopathy